Balance Sheet

Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

InMed Pharmaceuticals (INM) Capital Expenditures (2019 - 2024)

InMed Pharmaceuticals has reported Capital Expenditures over the past 4 years, most recently at $2.0 for Q1 2024.

For Q1 2024, Capital Expenditures changed N/A year-over-year to $2.0; the TTM value through Jun 2024 reached $31818.0, up 117.77%, while the annual FY2024 figure was $9293.0, 94.19% down from the prior year.
Capital Expenditures for Q1 2024 was $2.0 at InMed Pharmaceuticals, down from $31816.0 in the prior quarter.
Over five years, Capital Expenditures peaked at $250000.0 in Q3 2021 and troughed at -$214445.0 in Q4 2021.
A 4-year average of $14185.2 and a median of $3553.0 in 2022 define the central range for Capital Expenditures.